Ocera Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
The founders of Ocera Therapeutics recognize that the medical needs of patients with gastrointestinal and liver diseases are largely unmet, and they think they can do something about it. Their goal is to develop new therapeutic products for inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and liver disease sufferers by in-licensing clinical-stage compounds with promising efficacy and safety profiles.
You may also be interested in...
Signs of Movement in IBS Drug Development
Despite Big Pharma's struggles, the availability of compounds developed for other pain indications could energize start-ups' interest in irritable bowel syndrome.
Biodesy LLC
Second-harmonic generation is an optical phenomenon that occurs when a nonlinear surface combines photons of light to produce photons with twice the frequency and half the wavelength of the original photons. Biodesy is harnessing its power to measure protein conformation for drug discovery.
Jenken Biosciences Inc.
At present, there are no approved small molecule anti-inflammatory drugs for treating hepatitis C. Indeed, most drug R&D activity for hepatitis centers on new or improved anti-viral therapy rather than complications of the infection, e.g., the chronic inflammation that occurs in 80% of hepatitis cases. Jenken Biosciences hopes to change that. Jenken is repurposing two different, chemically similar, marketed compounds for new indications associated with chronic organ inflammation.